Key Takeaways from #ESMO20 on Melanoma

Key Takeaways from ESMO: updates on immunotherapy for melanoma

Roxana Dronca

1. There was some key data on immunotherapy for metastatic melanoma presented at this year's ESMO. Could you describe some of the most relevant findings?
2. Was this complete response predictive of long-term outcomes? - How would this impact clinical practice?
3. Was there any data presented at ESMO that might help address the needs of these relatively less responsive patients?
4. What other combinations were presented at ESMO this year?

Key Takeaways from ESMO: Updates in Targeted Therapy for Melanoma

Alexander CJ van Akkooi

1. What are the most exciting updates in targeted therapy for metastatic melanoma from this conference?
2. Did we learn anything new about adjuvant treatment from these presentations?
3. Finally, are there any novel targeted therapies that we should keep our eyes on?